Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English: A qualitative report from Children's Oncology Group's Diversity and Health Disparities Committee Language Equity Working Group. Read more about Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English: A qualitative report from Children's Oncology Group's Diversity and Health Disparities Committee Language Equity Working Group.
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Read more about Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function.
Time to diagnosis among young patients with cancer. Read more about Time to diagnosis among young patients with cancer.
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Read more about Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations. Read more about Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations.
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations. Read more about Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations.
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group. Read more about Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.
Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization. Read more about Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Financial assistance and other financial coping strategies after a pediatric cancer diagnosis. Read more about Financial assistance and other financial coping strategies after a pediatric cancer diagnosis.
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Read more about Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma.
